Jiangsu Vcare's New-generation TRK Inhibitor VC004 Obtains IND Approval from the US FDA
Published Time:
2024-10-17 17:29
Source:
On October 16, 2024, Jiangsu Vcare Pharmatech Co., Ltd. (referred to as "Jiangsu Vcare")'s independently developed new-generation anti-resistant TRK inhibitor VC004 achieved a significant milestone, obtaining Investigational New Drug (IND) approval from the US FDA. This fully demonstrates Jiangsu Vcare's excellent drug research and development capabilities and successful execution of the company's strategies centered on original innovation, high-quality standards, and a global layout.
The TRK gene fusion plays a key role in various cancers and is one of the important driving factors for cancer occurrence and development. Clinically, VC004 is primarily used to treat patients with NTRK gene fusion-positive tumors and is not limited to specific cancer types. As a new-generation TRK inhibitor, VC004 has demonstrated excellent efficacy and safety in multiple previous clinical studies in China. It is currently in the subject follow-up and pre-New Drug Application (NDA) preparation stage.
VC004 not only shows a higher clinical response rate compared with first-generation drugs but also exhibits significant anti-resistance to first-generation drugs. The previous clinical data were impressively presented at the 2024 American Society of Clinical Oncology (ASCO 2024) annual meeting: among patients who have not been treated with TRK TKI previously, the confirmed objective response rate (ORR) in the recommended phase 2 dose (RP2D) expansion group is 73.1% [95% CI, 52.2-88.4]; among 3 patients who have progressed after being treated with TRK-TKIs previously, the tumors of 2 patients have shrunk, and 1 patients has achieved a partial response (PR) (39.6%); for the vast majority of patients after treatment with VC004, the drug takes effect quickly and they obtain long-term survival benefits, and the longest duration of continuous remission of patients has exceeded 36 months; among 6 patients with baseline brain metastases, the intracranial lesions of 2 patients have shrunk by 61.8% and 25% respectively, and the non-target lesions of another 2 patients have disappeared after 4 months of treatment. In terms of safety, most treatment-related adverse events (TRAEs) that patients experienced are grade 1-2, and no fatal TRAEs have occurred. Compared with other drugs of the same kind, no new safety signals have been found.
Related News
28
2025
/
04
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the successful enrollment of the first participant in its Phase II clinical trial for VC005 topical gel, a self-developed next-generation highly selective JAK1 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD). The trial aims to evaluate the efficacy of VC005 gel in adult patients with mild-to-moderate AD, providing a critical data for dose selection in future clinical studies and further assesses the drug's safety profile.
View Details
11
2025
/
04
Recently, following joint review by Nanjing Jiangbei New Area Sci-Tech Bureau and Nanjing Municipal Science and Technology Bureau, the"Nanjing Key Laboratory for Artificial Intelligence (AI) Drug Design"established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) was approved as a 2025 Nanjing Key Laboratory. This marks authoritative recognition of Jiangsu Vcare’s scientific capabilities, with the Lab having achieved significant progress in drug design and molecular discovery.
View Details
26
2025
/
03
Jiangsu Vcare Launches Phase II Trial for VC005 Topical Gel in Mild-to-Moderate Atopic Dermatitis
On March 26, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) officially launched the Phase II clinical trial for its self-developed, highly selective JAK1 inhibitor VC005 gel for the topical treatment of mild-to-moderate atopic dermatitis (AD). The completed Phase I clinical study of VC005 gel demonstrated excellent safety and significant efficacy.
View Details
27
2025
/
01
Jiangsu Vcare Honored As: National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises; Top 100 China Pharma Innovation Seed Enterprises; Jiangsu Listed Sci-Tech Enterprise Cultivation Program; Jiangsu Chemical Innovative Drug Engineering Research Center; Top 500 China Hidden Unicorn Enterprises
View Details
26
2025
/
01
In January 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that its self-developed next-generation anti-resistant TRK inhibitor VC004 capsule has officially entered the domestic NDA preparation phase, initiating pre-NDA communications with regulatory authorities. Marking this milestone, Jiangsu Vcare has joined the top tier of domestic self-developed drugs targeting this pathway at remarkable speed.
View Details
22
2025
/
01
Jiangsu Vcare Secures Nearly CNY 200 Million in Series C+ Financing
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C+ financing round, raising nearly CNY 200 million. The round was jointly invested by Xinghe Venture Capital, Jinlong Investment, SDIC Capital, and Yangtze River Industry Group. The proceeds will accelerate clinical advancement of Jiangsu Vcare’s innovative drug pipelines, strengthen its integrated CRO/CDMO service ecosystem, enhance independent innovation capabilities, and advance strategic initiatives in synthetic biology and green chemistry. This brings Jiangsu Vcare’s total equity financing to over CNY 1 billion, demonstrating sustained capital market confidence.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn